FREM2 and glioblastoma: However, among the analyzed samples, the glioblastoma validation cohort showed the highest FREM2 expression of 8.5 TPM in the 58 analyzed glioblastoma samples followed by 4 TPM in the 50 samples included in the breast invasive carcinoma validation cohort.